Genflow Biosciences Share Discussion Threads

[moneymunch] 16/4/2024 20:56

Regeneron launches five-year $500m biotech fund

1 HOUR AGO



Biopharma giant commits $100m annually to Regeneron Ventures as it seeks to ‘fuel promising biotech innovation.’
Yesterday, as we revealed 2023 was another tough year for longevity investment, biotech heavyweight Regeneron quietly announced the formation of Regeneron Ventures, a new $500 million venture capital fund. As the fund’s exclusive limited partner, Regeneron has pledged $100 million annually over the next five years to invest in promising life sciences companies.

While the new fund’s investment mandate is broadly health focused, Regeneron Ventures says its interest is “skewed towards biotechnology, devices, tools, and enabling technologies.” The fund says that investment decisions will be guided by the quality of the science, people, and data, prioritizing “breakthrough innovation” despite the inherent risks and uncertainties. All of which should resonate well with founders in the longevity sector, offering a potential new source of funding for biotech startups targeting aging and age-related diseases.

[moneymunch] 16/4/2024 20:16

SIRT6 is an enzyme that plays an essential role in human health and contributes to epigenetic regulation of gene expression, mitochondrial health, and DNA repair. A review of literature suggests that SIRT6 could potentially help address diseases of aging, neurodegeneration, diabetes and obesity, in addition to depression. Arrivo is exploring the potential of SP-624 in multiple therapeutic areas beyond depression.

[moneymunch] 16/4/2024 19:05

Arrivo Bio Initiates Large Phase 2b Clinical Trial in Major Depressive Disorder with Novel SIRT6 Activator

Epigenetic mechanism of action offers a promising new approach to tackling MDD

April 16, 2024 08:00 AM Eastern Daylight Time
MORRISVILLE, N.C.--(BUSINESS WIRE)--

Arrivo Bio announced today a significant step forward in the fight against major depressive disorder (MDD) with the dosing of the first patient in the SP-624-202 clinical trial.

“The initiation of this study is an exciting milestone for Arrivo and the SP-624 program. Despite existing treatments, people with Major Depression often do not achieve remission and suffer unwanted side effects”


This registration-quality Phase 2b study will enroll 450 subjects with MDD and evaluate the effectiveness of SP-624, a SIRT6 activator and novel mechanism of action, compared to placebo in treating adults with Major Depressive Disorder. The SP-624-202 study will assess the change from baseline on the Montgomery-Åsberg Depression Rating Scale (MADRS) as its primary endpoint. The MADRS is a 10-item depression rating scale commonly used to assess the severity of depression in clinical trials. The large number of subjects will enable the study to explore several other investigator and patient-rated endpoints and exploratory biomarkers.

SIRT6 is an enzyme that plays an essential role in human health and contributes to epigenetic regulation of gene expression, mitochondrial health, and DNA repair. A review of literature suggests that SIRT6 could potentially help address diseases of aging, neurodegeneration, diabetes and obesity, in addition to depression. Arrivo is exploring the potential of SP-624 in multiple therapeutic areas beyond depression.

“The initiation of this study is an exciting milestone for Arrivo and the SP-624 program. Despite existing treatments, people with Major Depression often do not achieve remission and suffer unwanted side effects,” said Dr. Joel Raskin, Chief Medical Advisor at Arrivo. “This large study will significantly augment our current data on SP-624, which has the potential to be a truly transformative treatment for patients suffering from depression.”

Arrivo remains committed to advancing groundbreaking research in MDD and looks forward to sharing further developments from the SP-624-202 study. For more information on Arrivo or the SP-624-202 study, please visit www.arrivobio.com

[moneymunch] 13/4/2024 08:35

10th - 11th June 2024 - Organised by Longevity Technology who hold 3%. Gla ;-)


New international event program launches to bring longevity entrepreneurs and investors together.

Founders Forum and Longevity.Technology today announced the launch of the Founders Longevity Forum, a premier event series designed to educate and connect investors with the vast potential within the longevity market.

The inaugural Founders Longevity Forum will take place at Olympia London during the renowned London Tech Week, focusing on a sector that is projected to exceed $600 billion by 2025. This partnership aims to foster meaningful connections between startups, venture capitalists (VCs), corporate venture capitalists (CVCs), family offices and CEOs leading the charge in longevity.

Brent Hoberman, Co-Founder and Executive Chair of Founders Forum Group, said: “Longevity is becoming a mega trend as science makes increased healthspans more realistic, converging with a wider shift towards preventative healthcare.

“We’ve noticed a need to connect top scientists and innovative startups with funds to help them turn their dreams into reality. By bringing together the best and brightest minds working on longevity today, we can galvanize progress in this area and transform the demographic landscape.”

Taking place on New international event program launches to bring longevity entrepreneurs and investors together.4, the Founders Longevity Forum will address the investment opportunities across the longevity space, from established longevity business models such as diagnostics, longevity clinics and supplements, through to cutting-edge longevity biotech companies poised to revolutionize the biotech industry and transform society.

The event will also benefit from an advisory panel that has decades of longevity and geroscience expertise between them; the panel includes Eric Verdin, Andrea Maier, Jim Mellon and Aubrey de Grey, with further members to be announced.

“Multiple longevity events are happening and they’re all great, but few are specifically focused on bringing more investors into this rapidly accelerating field,” said Phil Newman, Founder and CEO, Longevity.Technology.

“We plan to stage events in London, Abu Dhabi and San Francisco initially to accelerate longevity investment globally, and catalyze a wave of innovation and collaboration that will redefine the future of human health.”

“We’re keen to educate investors on the vast opportunities in longevity whilst fostering meaningful connections for startups and scaleups in this niche,” said Carolyn Dawson, CEO, Founders Forum Group.

“Helping create these connections is central to our mission at Founders Forum Group as we seek to empower entrepreneurs at every stage of their journeys; with Longevity.Technology as our partner, we can forge formative alliances that propel longevity innovation.”

Key highlights of the Founders Longevity Forum:

Exclusive event – The Founders Longevity Forum will host a minimum of 120 approved guests, including high-caliber investors, family offices, longevity founders and VIPs.

Comprehensive program – guests will enjoy a half-day of content, a welcome reception, a full-day program and automatic registration for London Tech Week.

Global reach – following the London event, the Founders Longevity Forum will travel to Abu Dhabi and San Francisco.

Longevity takes center stage – The Longevity Village at London Tech Week will elevate this dynamic industry, showcasing the companies applying new technologies to extend human healthspan.

[moneymunch] 13/4/2024 08:28

Major Shareholders


ERIC LEIRE 124,000,000 35.5%
PREMIER MITON 32,000,000 9.2%
ARIAN BEESTON 17,475,000 5.0%
JONATHAN MARK SWANN 16,874,000 4.8%
SAMANTHA BAUER 14,500,000 4.1%
LONGEVITY TECH FUND 10,499,998 3.0%
SARAH BEESTON 10,000,000 2.9%

[moneymunch] 10/4/2024 21:01

Excellent, not long before this bounces Big!!! Gla :-)

[steg] 10/4/2024 20:57

As a wise man once said, follow the 💰 💰

[northeast14] 10/4/2024 19:51

£400k buy from Premier Miton! Very good show of confidence by them in Genflow

[northeast14] 09/4/2024 19:08

Still waiting for premier miton to TR1… are they still buying on open market?

[moneymunch] 09/4/2024 15:57

Eric's £50k share subscription declared along with another 1.8% for Jonathan Swann who declared his 3% back in March. The smart Money is accumulating. Gla :-)

[moneymunch] 08/4/2024 15:12

Yes indeed Northeast, the only way is UP!!! More good news coming soon. Gl :-)

[northeast14] 08/4/2024 12:05

There is only one place this cashed up company is going and that’s far North of 1.7p

[northeast14] 08/4/2024 12:04

None of the placing shares can be sold. And all of the people in the raise are serious investors or BOD or institutions. There will be no dumping

[davealders] 08/4/2024 09:45

Spot on Moneymunch.

[moneymunch] 08/4/2024 09:39

Lol...you'll regret not buying in because of your blinkered view, the £755k raise was to facilitate the arrival of institutional investors, all the directors subscribed including £50k by Genflow's CEO....much more to come with US investors in the pipeline...this is going to big, the current bargain low and miniscule market cap offers tremendous UPside opportunity. Gl :-)

[lookinggood] 08/4/2024 09:27

1.25p placing imNot buying so placees can dump out

[moneymunch] 08/4/2024 09:13

Lol...Good luck with APH, but Genflow's upside this year is potentially going to be stellar...watch this space. :-)

[blackhorse23] 08/4/2024 09:07

Money moving to APH , dividends announcement in 10 days

[blackhorse23] 08/4/2024 09:07

Safer to get out now lol

[moneymunch] 08/4/2024 08:55

Supply and demand, the majority of free float is now very tightly held for bigger and better things to come....On and UP!!! Gl :-)

[steg] 08/4/2024 08:27

Can’t buy in any quantity at all anyone else the same?

[moneymunch] 07/4/2024 23:06

Courtesy of Porter on Lse, an excellent and informative interview and very encouraging on prospects and potential going forward. Exciting times ahead. Gla :-)

US fast track trials

Interview with Zak Mir:



- US fast tracking Nash trials

- 100,000 patients on liver transplant list in US alone

- talk of further US institutions coming in

- delivering Nash treatment like a vaccination - think how much money was made on covid…

[moneymunch] 07/4/2024 19:32

Plenty to look forward to Northeast, but momentum was lost in September 2023 update confirming the Human Clinical Trials for Nash wouldn't be for at least 18 months ( 2025 ) with many pi's selling up looking for more immediate returns, but at least the trials will be carried out on Nash patients rather than healthy volunteers and I guess Genflow had to meet further criteria from the EMA associated with manufacturing/dosage and delivery etc, but as you say, Eric will want everything covered and every chance the patent could be approved and granted by then which will be massive news, and highly significant and of major interest to any potential partners. Exciting times and fully expect to see the share price heading UPwards from this new financial year, with plenty of money flooding back into the market and any cut in interest rates will be very well received. Gl :-)

[northeast14] 07/4/2024 18:06

Money,
Genflow has the mice trial results to show the FDA before publication! No one else has done anything like this. We are well ahead of the game as data is always needed. I’m not 100% sure why we aren’t going into Human trials this year. I guess like Eric has said from day 1 he wants to have everything covered and do it correctly. This patent will be a game change.

Not to mention we have the other two programs moving along nicely too. News can come on any front now

[moneymunch] 07/4/2024 17:19

You can't imagine Madrigal acquiring or partnering one of the big players and so Genflow could be on their radar, given the compelling potency and importance of Sirt6 in multiple disease targets and involvement and influence/activation over incretin-modulatiion, highlighted in the above article, and also includes GLP-1's currently in development as obesity therapies which are thought to have a high chance of being of medical benefit to Nash etc. Gla :-)


.........


These findings establish the involvement of SIRT6 in the inflammatory pathways of diabetic atherosclerotic lesions and suggest its possible positive modulation by incretin, the effect of which is associated with morphological and compositional characteristics of a potential stable plaque phenotype.